REVIEW ARTICLE

# Bispecific antibodies in follicular lymphoma

Imran A. Nizamuddin and Nancy L. Bartlett

Department of Medicine, Division of Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA

**Correspondence:** N.L. Bartlett
nbartlet@wustl.edu

**Received:** August 16, 2024.
**Accepted:** October 18, 2024.
**Early view:** October 31, 2024.

**https://doi.org/10.3324/haematol.2024.285245**

**Supplementary Table S1.** Ongoing trials investigating bispecific antibodies in follicular lymphoma.

| Treatment | Trial | Phase | Duration of Treatment | Notes |
|---|---|---|---|---|
| *CD3-CD20 Bispecific Antibodies: Frontline Therapy* | | | | |
| | | | | |
| Rituximab vs. mosunetuzumab | NCT06337318 | III | 21-day cycles up to 8 cycles | - Enrolling patients with low tumor burden |
| Mosunetuzumab vs. investigator choice chemoimmunotherapy | NCT06284122 | III | Induction: 28-day cycles up to 12 cycles<br>Maintenance: 8-week cycles up to 9 cycles | - 21-day cycle for cycle 1<br>- Enrolling patients with FLIPI 2-5 |
| Odronextamab vs. chemoimmunotherapy (R-CHOP, BR, R-CVP) | OLYMPIA-1 (NCT06091254) | III | 21-day cycles for 6 cycles, followed by maintenance | |
| Odronextamab + chemotherapy + maintenance vs. rituximab + chemotherapy +/- maintenance | OLYMPIA-2 (NCT06097364) | III | 21-day cycles for 6 cycles, followed by maintenance | |
| Lenalidomide + epcoritamab | NCT06112847 | II | 28-day cycles up to 12 cycles | |
| Tazemetostat + mosunetuzumab | NCT05994235 | II | 28-day cycles up to 12 cycles | |
| Epcoritamab + rituximab | NCT05783609 | II | 28-day cycles up to 9 cycles | - 6-week cycle for cycle 1 |

| | | | | |
|---|---|---|---|---|
| Mosunetuzumab + polatuzumab vedotin | NCT05410418 | II | 21-day cycles up to 8 cycles (if CR) or 17 cycles (if PR/SD after C8) | - |
| Mosunetuzumab | NCT05389293 | II | 21-day cycles up to 8 cycles (if CR) or 17 cycles (if PR/SD after C8) | |
| Mosunetuzumab +/- lenalidomide | BrUOG-401 (NCT04792502) | II | 21-day cycles for 4 cycles followed by response assessment. If CR, 4 additional cycles of mosunetuzumab. If PR, 4 additional cycles with addition of lenalidomide. If persistent PR after C8, 4 additional cycles with addition of lenalidomide | - MZL also eligible |
| Mosunetuzumab +/- polatuzumab vedotin and obinutuzumab | NCT05169658 | II | Part A: 21-day cycles up to 8 cycles<br>Part B: 21-day cycles for 6 cycles | - Patients without CR after Part A proceed to Part B (addition of polatuzumab vedotin and Obinutuzumab)<br>- MZL also eligible |
| Obinutuzumab + glofitamab | NCT05783596 | II | 21-day cycles up to 12 cycles | - 36-day cycle for cycle 1<br>- MZL also eligible |
| ***CD3-CD20 Bispecific Antibodies: Relapsed/Refractory Disease*** | | | | |
| Mosunetuzumab + lenalidomide vs. | CELESTIMO (NCT04712097) | III | 28-day cycles up to 12 cycles | |

| | | | | |
|---|---|---|---|---|
| rituximab + lenalidomide | | | | |
| Epcoritamab + rituximab/lenalidomide (R2) | EPCORE FL-1 (NCT05409066) | III | 28-day cycles up to 12 cycles | |
| Odronextamab + lenalidomide vs. rituximab/lenalidomide (R2) | OLYMPIA-5 (NCT06149286) | III | 21-day cycles up to 12 cycles | |
| Epcoritamab + lenalidomide vs. investigator choice | REFRACT (NCT05848765) | II | 28-day cycles up to 12 cycles | - Investigational agents for rounds 2 and 3 not yet selected |
| Mosunetuzumab | MERLIN (NCT05849857) | II | 21-day cycles up to 8 cycles (if CR) or 17 cycles (if PR/SD after C8) | - Enrolling patients with POD24 |
| ***CD3-CD20 Bispecific Antibodies: Any Line of Treatment*** | | | | |
| Mosunetuzumab + lenalidomide | NCT04246086 | Ib/II | 28-day cycles up to 12 cycles | - 21-day cycle for cycle 1<br>- Arms testing IV vs SC formulation |
| ***Other Bispecific Antibodies: Relapsed/Refractory Disease*** | | | | |
| Lenalidomide + blinatumomab | NCT02568553 | I | Induction: Blinatumomab D1-56<br>Consolidation: Blinatumomab D1-7 in 28-day cycles for 6 cycles<br>Maintenance: No blinatumomab | - Enrolling patients with R/R B-cell NHL |

C: cycle; CR: complete response; D: day; FLIPI: Follicular Lymphoma; IPI: International Prognostic Index; IV: intravenous; MZL: marginal zone lymphoma; NHL: non-Hodgkin lymphoma; POD24: progression of disease within 24 months; PR: partial response; R/R: relapsed/refractory; SC: subcutaneous; SD: stable disease